Kairos Pharma (NYSEAM:KAPA) - Stock Price, News & Analysis

KAPA Stock Overview

A clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. More details

KAPA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 56.8% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($21M)

+ 1 more risk

Kairos Pharma, Ltd. Competitors

bioAffinity Technologies

NasdaqCM:BIAF

US$19.0m

ProMIS Neurosciences

NasdaqCM:PMN

US$20.7m

Unity Biotechnology

NasdaqGS:UBX

US$19.2m

MEI Pharma

NasdaqCM:MEIP

US$18.5m

Price History & Performance

Summary of all time highs, changes and price drops for Kairos Pharma
Historical stock prices
Current Share Price	US$1.60
52 Week High	US$4.00
52 Week Low	US$1.22
Beta	0
11 Month Change	10.34%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-38.46%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	KAPA	US Biotechs	US Market
7D	3.2%	2.5%	2.2%
1Y	n/a	16.1%	31.6%

Return vs Industry: Insufficient data to determine how KAPA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how KAPA performed against the US Market.

Price Volatility

Is KAPA's price volatile compared to industry and market?
KAPA volatility
KAPA Average Weekly Movement	22.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: KAPA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine KAPA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	n/a	John Yu	kairospharma.com

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-?ß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors.

Kairos Pharma, Ltd. Fundamentals Summary

How do Kairos Pharma's earnings and revenue compare to its market cap?
KAPA fundamental statistics
Market cap	US$20.55m
Earnings (TTM)	-US$2.74m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-7.5x

P/E Ratio

Is KAPA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KAPA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$2.74m
Earnings	-US$2.74m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.21
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	4.3%

How did KAPA perform over the long term?

See historical performance and comparison